Intestinal permeability: Prediction from theory

Oral Drug Absorption: Prediction and Assessment

Volumn , Issue , 2000, Pages 31-49

  van de Waterbeemd, Han ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042444175     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (64)

1. Smith P. Special issue. Adv Drug Deliv Rev 1997; 23(1-3).
2. Chan OH, Stewart BH. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1996; 1: 461-473.
3. van de Waterbeemd H. The fundamental variables of the biopharmaceutics classification system (BCS)-a commentary. Eur J Pharm Sci 1998; 7: 1-3.
4. Yalkowski SH, Banerjee S. Aqueous Solubility. Methods of Estimation for Organic Compounds. New York: Marcel Dekker, 1992.
5. Yalkowski SH, Valvani SC, Roseman TJ. Solubility and partitioning VI: octanol solubility and octanol-water partition coefficients. J Pharm Sci 1983; 72: 866-870.
6. El Tayar N, Testa B, Carrupt PA. Polar intermolecular interactions encoded in partition coefficients: an indirect estimation of hydrogen-bond parameters of polyfunctional solutes. J Phys Chem 1992; 96: 1455-1459.
7. Avdeef A. Assessment of distribution-pH profiles. In: Pliska V, Testa B, van de Waterbeemd H, eds. Lipophilicity in Drug Action and Toxicology. Weinheim: VCH, 1996:109-137.
8. Testa B, Seiler P. Steric and lipophilic components of the hydrophobic fragmental constant. Arzneim Helforschung 1981; 31: 1053-1058.
9. van de Waterbeemd H, Testa B. The parameterization of lipophilicity and other structural properties in drug design. Adv Drug Des 1987; 16: 85-225.
10. Raevsky OA, Schaper KJ, Seydel JK. H-bond contribution to octanol-water partition coefficients of polar compounds. Quant Struct Act Relat 1995; 14: 433-436.
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
12. van de Waterbeemd H, Kansy M. Hydrogen-bonding capacity and brain penetration. Chimia 1992; 46: 299-303.
13. van de Waterbeemd H, Camenisch G, Folkers G, Raevsky OA. Estimation of Caco-2 permeability using calculated molecular descriptors. Quant Struct Act Relat 1996; 15: 480-490.
14. Kamlet MJ, Doherty RM, Abboud JLM, Abraham MH, Taft RW. Linear solvation energy relationships: 36. Molecular properties governing solubilities of organic nonelectrolytes in water. J Pharm Sci 1986; 75: 338-349.
15. Carrupt P, Testa B, Gaillard P. Computational approaches to lipophilicity: methods and applications. In: Lipkowitz KB, Boyd DB, eds. Reviews in Computational Chemistry. Vol. 11. New York: Wiley-VCH, 1997: p. 241-315.
16. van de Waterbeemd H, Mannhold R. Programs and methods for calculation of log P values. Quant Struct Act Relat 1996; 15: 410-412.
17. Moriguchi I, Hirono S, Nakagome I, Hirano H. Comparison of reliability of log P values for drugs calculated by several methods. Chem Pharm Bull 1994; 42: 976-978.
18. Suzuki T, Kudo Y. Automatic log P estimation based on combined additive modeling methods. J Comput Aided Mol Des 1990; 4: 155-198.
19. Junghans M, Pretsch E. Estimation of partition coefficients of organic compounds: local database modeling with uniform-length structure descriptors. Fre-senius J Anal Chem 1997; 359: 88-92.
20. Wang R, Fu Y, Lai L. A new atom-additive method for calculating partition coefficients. J Chem Inf Comput Sci 1997; 37: 615-621.
21. Yang CY, Cai SJ, Liu H, Pidgeon C. Immobilized artificial membranes-screens for drug membrane interactions. Adv Drug Deliv Rev 1996; 23: 229-256.
22. Ong S, Liu H, Pidgeon C. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996; 728: 113-128.
23. Lundahl P, Beigi F. Immobilized liposome chromatography of drugs for model analysis of drug-membrane interactions. Adv Drug Deliv Rev 1997; 23: 221-227.
24. Bodor N, Huang MJ. An extended version of a novel method for estimation of partition coefficients. J Pharm Sci 1992; 81: 272-281.
25. Paulett GM, Okumu FW, Borchardt RT. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm Res 1997; 14: 164-168.
26. Adson A, Raub TJ, Burton PS, Barsuhn CL, Hilgers AR, Audus KL, Ho NFH. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J Pharm Sci 1994; 83: 1529-1536.
27. Pauletti GM, Gangwar S, Okumu FW, Siahaqan TJ, Stella VJ, Borchardt RT. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm Res 1996; 13: 1615-1623.
28. Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci USA 1994; 91: 68-72.
29. Fischer H. The Diffusion of Drugs Through Biological Membranes. Ph.D. dissertation, University of Basel, Switzerland, 1998.
30. Collander R, Bärlund H. Permeabilitätsstudien an Chara ceratophylla. Acta Bot Fenn 1932; 11: 1-114.
31. Stein WD. In: The Movement of Molecules Across Cell Membranes. London: Academic Press, 1967:65-125.
32. Seiler P. Interconversion of lipophilicities from hydrocarbon/water systems into the octanol/water system. Eur J Med Chem 1974; 9: 473-479.
33. Lien EJ, Lien LL, Gao H. Structure-system-activity relationship analysis of drug disposition. In: Sanz F, Giraldo J, Manaut F, eds. QSAR and Molecular Modelling. Barcelona: Prous, 1995:94-100.
34. Basak SC, Gute BD, Drewes LR. Predicting blood-brain transport of drags: a computational approach. Pharm Res 1996; 13: 775-778.
35. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997; 14: 568-571.
36. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996; 85: 32-39.
37. 2 receptor histamine antagonists. J Med Chem 1988; 31: 656-671.
38. 1 antihistaminic agents in relation to their central sedative side-effects. Eur J Pharm Sci 1994; 2: 373-384.
39. Buur A, Trier L, Magnusson C, Artursson P. Permeability of 5-fluorouracil and prodrugs in Caco-2 cell monolayers. Int J Pharm 1996; 129: 223-231.
40. von Geldern TW, Hoffman DJ, Kester JA, Nellans HN, Dayton BD, Calzadilla SV, Marsch KC, Hernandez, Chiou W, Dixon DB, Wu-Wong JR. Opgenorth TJ. Azole endothelin antagonists. 3. Using Alog P as a tool to improve absorption. J Med Chem 1996; 39: 982-991.
41. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
42. Stehle RG, Higuchi WI. In vitro model for transport of solutes in three-phase system I: theoretical principles. J Pharm Sci 1972; 61: 1922-1930.
43. Camenisch G, Folkers G, van de Waterbeemd H. Review of theoretical passive drug absorption models: historical background, recent developments and limitations. Pharm Acta Helv 1996; 71: 309-327.
44. Leahy DE, Lynch J, Taylor DC. Mechanisms of absorption of small molecules. In: Prescott LF, Nimmo WS, eds. Novel Drug Delivery and Its Therapeutic Application. New York: Wiley, 1989:33-44.
45. Camenisch G, Folkers G, van de Waterbeemd H. Shapes of membrane perme-ability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur J Pharm Sci 1998; 6: 321-329.
46. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drug’s lipophilicity and molecular weight. Eur J Pharm Sci 1998; 6: 313-319.
47. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drag Deliv Rev 1996; 22: 67-84.
48. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 1997; 14: 763-766.
49. Wils P, Warnery A, Phung-Ba V, Legrain S, Scherman D. High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 1994; 2: 654-658.
50. Hamilton HW, Steinbaugh BA, Stewart BH, Chan OH, Schmid HL, Schroeder R, Ryan MJ, Keiser J, Taylor MD, Blankley CJ, Kaltenbronn JS, Wright J, Hick J. Evaluation of physicochemicai parameters important to the oral bioavailability of peptide-like compounds: implications for the synthesis of renin inhibitors. J Med Chem 1995; 38: 1446-1455.
51. Conradi RA, Hilgers AR, Ho NFH, Burton PS. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm Res 1992; 9: 435-439.
52. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
53. Gan LSL, Thakker DR. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Revs 1997; 23: 77-98.
54. Camenisch G. Drug Transport Across Membranes. Structure-Property Correlations in the Prediction of Passive Membrane Permeation. Ph.D. dissertation, ETH Zürich, Switzerland, 1996.
55. Norinder U, Österberg T, Artursson P. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parameterization and PLS statistics. Pharm Res 1997; 14: 1786-179.
56. Levet-Trafit B, Gruyer MS. Marjanovic M, Chou RC. Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci 1996: 58: 359-363.
57. van de Waterbeenid H. Application of physicochemical methods to oral drug absorption estimation. Eur J Phann Sci 1997; 5(suppl 2): S26-S27.
58. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41: 1007-1010.
59. Sietsema WK. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 1989; 27: 179-211.
60. Benet LZ, Øie S. Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Linibird LE, eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996:1712-1792.
61. Lenncrnäs H. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 1995; 12: 1573-1582.
62. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 1996: 20:99-112.
63. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaiaj N, Tapiero H, Priebc W, Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. Biochemistry 1997; 36:2679-2685.
64. Seelig A. A general pattern for substrate recognition by P-glycoprotein, Eur J Biochem 1998; 25:252-261.